Impact of mycolytic therapy on the production of active oxygen formS in the blood of patients with an exacerbation of chronic obstructive pulmonary disease


Aim. To study the production of active oxygen forms (AOF) in the blood of patients with an exacerbation of chronic obstructive pulmonary disease (COPD) and the effect of the mycolytic agent Ambroxol on this process.
Subjects and methods. Fifty-two patients with an exacerbation of COPD were examined. The patients were divided into 2 groups: 1) a study group (n = 25) received conventional therapy (antibiotics, bronchodilators, glucocorticosteroids) and Ambroxol inhalation; 2) a control group (n = 27) had conventional therapy and placebo (saline) inhalation. The blood production of AOF was studied by luminol-dependent chemiluminescence (CL) assay.
Results. The intensity of whole blood CL was increased in patients with COPD. Ambroxol therapy reduced blood AOF generation and improved clinical parameters. On the contrary, the high intensity of blood CL remained and a slowing trend in the symptoms of the disease was noted in the control group.
Conclusion. The use of Ambroxol in COPD exacerbations corrected AOF production in the blood of the patients and enhanced the efficiency of their treatment.


  1. Global initiative for chronic obstructive lung disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report: updated 2006
  2. Vandervoorde J., Verbanck S., Gijssels L. et al. Early detection of COPD: a case finding study in general practice. Respir. Med. 2007; 101: 525-530.
  3. Langsetmo L., Platt R. W., Ernst P., Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am. J. Crit. Care Med. 2008; 177 (4): 396-401.
  4. Donaldson G. C., Seemungal T. A. R., Bhowmik A., Wedzicha J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57 (10): 847-852.
  5. McGhan R., Radcliff T., Fish R. et al. Predictors of rehospitalisation and death after a severe exacerbation of COPD. Chest 2007; 132 (6): 1748-1755.
  6. Абдрахманова Л. М., Фархутдинов У. Р., Фархутдинов Р. Р. Особенности экспрессии активных форм кислорода клетками крови у больных хроническим бронхитом. Тер. арх. 2001; 3: 45-48.
  7. Соодаева С. К. Роль свободнорадикального окисления в генезе ХОБЛ. Атмосфера 2002; 4: 24-25.
  8. Янковский О. Ю. Токсичность кислорода и биологические системы (эволюционные, экологические и медико-биологические аспекты). СПб.: Игра; 2000.
  9. Hasegawa I., Niisato N., Iwasaki Y., Marunaka Y. Ambroxol-induced modification of ion transport in human airway Calu-3 epithelia. Biochem. Biophys. Res. Commun. 2006; 343 (2): 475-482.
  10. Yang B., Yao D. F., Ohuchi M. et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19 (5): 952-958.
  11. Gibbs B. F., Schmutzler W., Vollrath I. B. Ambroxol inhibits the release of hista- ' mine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm. Res. 1999; 48 (2): 86-93.
  12. Stetinova V., Herout V., Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin. Exp. Med. 2004; 4 (3): 152-158.
  13. Anthonisen N. R., Manfreda J., Warren C. P. W. et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
  14. Меньшиков В. В. (ред.). Лабораторные методы исследования в клинике. М.: Медицина; 1987.
  15. Фархутдинов Р. Р. Методы исследования хемилюминесценции биологического материала на хемилюминомере ХЛ-003. В кн.: Методы оценки антиоксидантной активности веществ лечебного и профилактического назначения. М.: РУДН; 2005. 147-155.
  16. Куницина Ю. Л., Шмелев Е. И. Противовоспалительная терапия больных при хронической обструктивной болезни легких. Пульмонология 2003; 2: 111-116.
  17. Коган А. Х. Фагоцитзависимые кислородные - свободнорадикальные механизмы аутоагрессии в патогенезе внутренних болезней. Вестн. РАМН. 1999; 2: 3-10.
  18. Jang Y. Y., Song J. H., Shin Y. K. et al. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol. and Toxicol. 2003; 92 (4): 173-179.
  19. Zhao S. P., Guo Q. L., Wang R. K., Wang E. Oxidative and anti-oxidative effects of ambroxol on acute hydrochloric acid-induced lung injury in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004; 29 (5): 586-598.

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies